On December 4, 2024, Cardio Diagnostics Holdings received a second letter from Nasdaq granting an additional 180-day period until June 2, 2025, to meet the $1.00 minimum bid price requirement. This extension follows the initial period ending December 2, 2024, during which the company failed to regain compliance.The extension is based on Cardio Diagnostics meeting other listing requirements, except for the minimum bid price. The company plans to address the deficiency, potentially through a reverse stock split. If compliance is not achieved by the deadline, Nasdaq may delist the company's securities, though an appeal option exists.The company remains committed to resolving the issue and regaining compliance, with no immediate effect on stock trading.

On December 4, 2024, Cardio Diagnostics Holdings received a second letter from Nasdaq granting an additional 180-day period until June 2, 2025, to meet the $1.00 minimum bid price requirement. This extension follows the initial period ending December 2, 2024, during which the company failed to regain compliance.The extension is based on Cardio Diagnostics meeting other listing requirements, except for the minimum bid price. The company plans to address the deficiency, potentially through a reverse stock split. If compliance is not achieved by the deadline, Nasdaq may delist the company's securities, though an appeal option exists.The company remains committed to resolving the issue and regaining compliance, with no immediate effect on stock trading.